Utility of plasma p‐tau217 as a secondary outcome for clinical trials across AD continuum
Utility of plasma p‐tau217 as a secondary outcome for clinical trials across AD continuum
About this item
Full title
Author / Creator
Ferreira, Pamela C.L. , Bellaver, Bruna , Povala, Guilherme , Aguzzoli, Cristiano Schaffer , Ferrari‐Souza, João Pedro , Leffa, Douglas Teixeira , Lussier, Firoza Z , Madeiros, Marina Scop , Zalzale, Hussein , Rohden, Francieli , Soares, Carolina , Abbas, Sarah , Bauer‐Negrini, Guilherme , Karim, Helmet T. , Hong, Chang Hyung , Roh, Hyun Woong , Tudorascu, Dana , Karikari, Thomas K , Snitz, Beth E. , Son, Sang Joon and Pascoal, Tharick A.
Publisher
Hoboken: John Wiley and Sons Inc
Journal title
Language
English
Formats
Publication information
Publisher
Hoboken: John Wiley and Sons Inc
Subjects
More information
Scope and Contents
Contents
Background
Blood‐based biomarkers offer a cost‐effective and simple alternative for clinical use in the context of Alzheimer's disease (AD). It has already been shown that plasma phosphorylated tau at threonine 217 (p‐tau217) is associated with amyloid (Aβ), neurofibrillary tau tangles, and cognitive decline. Longitudinal studies confirmed its a...
Alternative Titles
Full title
Utility of plasma p‐tau217 as a secondary outcome for clinical trials across AD continuum
Authors, Artists and Contributors
Author / Creator
Bellaver, Bruna
Povala, Guilherme
Aguzzoli, Cristiano Schaffer
Ferrari‐Souza, João Pedro
Leffa, Douglas Teixeira
Lussier, Firoza Z
Madeiros, Marina Scop
Zalzale, Hussein
Rohden, Francieli
Soares, Carolina
Abbas, Sarah
Bauer‐Negrini, Guilherme
Karim, Helmet T.
Hong, Chang Hyung
Roh, Hyun Woong
Tudorascu, Dana
Karikari, Thomas K
Snitz, Beth E.
Son, Sang Joon
Pascoal, Tharick A.
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11714363
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11714363
Other Identifiers
ISSN
1552-5260
E-ISSN
1552-5279
DOI
10.1002/alz.092042
